Rivaroxaban Tablet, Film Coated
Product Images NDC 76282-774

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 76282-774). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals,inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

180 Tablets-label.jpg (180 Tablets Label)

Rivaroxaban 2.5 mg film-coated tablets label by Exelan Pharmaceuticals, Inc. The label shows 180 tablets with a prescription-only designation, listing storage instructions, dosage details, and manufacturer information. The tablet image is beige and round, and the NDC number 76282-774-18 is displayed.*

FDA Label Image

Fig_10.jpg (Fig 10)

A Kaplan-Meier curve chart showing cumulative incidence rate (%) over days from randomization for two treatment groups: Rivaroxaban and Placebo. The solid line represents Rivaroxaban and the dashed line represents Placebo, illustrating lower incidence rates for Rivaroxaban. A table below displays the number of subjects at risk at multiple time points for each group, and the hazard ratio with 95% confidence interval is provided for the comparison between Rivaroxaban and Placebo.*

FDA Label Image

Fig_11.jpg (Fig 11)

A cumulative incidence rate line graph comparing Rivaroxaban and placebo treatment groups over days from randomization up to 1095 days. The y-axis represents cumulative incidence rate (%) and the x-axis shows days from randomization. A hazard ratio with 95% confidence interval comparing Rivaroxaban versus placebo is included alongside the number of subjects at risk for both groups at various time points.*

FDA Label Image

Fig_12.jpg (Fig 12)

A forest plot comparing the efficacy outcomes of Rivaroxaban 2.5 mg versus placebo across various subgroups including age, sex, weight, baseline diabetes, coronary artery disease, and others. The horizontal axis represents hazard ratios (HR) with confidence intervals, showing the relative effect of Rivaroxaban versus placebo on the primary efficacy endpoint.*

FDA Label Image

Fig_2.jpg (Fig 2)

A chart depicting the pharmacokinetic (PK) parameters Cmax and AUC fold change with 90% confidence intervals for Rivaroxaban in different population subgroups. The chart compares end-stage renal disease, varying degrees of renal impairment, age groups, body weight categories, and hepatic impairment against normal reference values, illustrating changes relative to the reference for each subgroup.*

FDA Label Image

Fig_3.jpg (Fig 3)

A forest plot chart showing the pharmacokinetic (PK) effects of various interacting drugs on rivaroxaban. The x-axis represents fold change relative to rivaroxaban alone, ranging from 0.25 to 4, with confidence intervals shown. The y-axis lists interacting drugs categorized by their mechanism (P-gp and CYP3A inhibitors, CYP3A inducers, and other drugs) and measures changes in Cmax, AUC, or both.*

FDA Label Image

Fig_9.jpg (Fig 9)

A line graph showing cumulative incidence rate (%) over days from randomization (up to 1095 days) comparing Rivaroxaban and placebo. The graph includes lines representing Rivaroxaban (solid) and placebo (dashed), with the number of subjects at risk displayed below. A hazard ratio with 95% confidence interval for Rivaroxaban versus placebo is also shown.*

FDA Label Image

Rivaroxaban Structure.jpg (Rivaroxaban Structure)

Chemical structure of Rivaroxaban, an active ingredient in the tablet dosage form of this prescription drug by Exelan Pharmaceuticals, Inc. The diagram shows the molecule's arrangement, including rings and functional groups characteristic to Rivaroxaban.*

FDA Label Image

Label_60 Tablets.jpg (Label 60 Tablets)

Rivaroxaban Tablets USP 2.5 mg film-coated oral tablets label. Contains 60 tablets, labeled for prescription use only. Manufactured for Exelan Pharmaceuticals, Inc. The label includes storage instructions and a notice to dispense the accompanying Medication Guide. Barcode and NDC 76282-774-60 are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.